Soliris (eculizumab), one of the most expensive drugs in the world, will be reimbursed by the decision of the Ministry of Health. The drug is used primarily by children suffering from atypical hemolytic uremic syndromes, i.e. aHUS, and paroxysmal nocturnal hemoglobinuria. The pharmaceutical cannot be replaced by anything else.
Although the therapy is very expensive, the Ministry of Health found money. – After long talks, negotiations on the side of the payer and a good economic year, we came to the conclusion that we must help small patients for whom this drug is the only therapeutic option. Negotiations were quite long, difficult and complex. The producer agreed to accept the terms proposed by MZ, said Marcin Czech.
The minister emphasizes that the Ministry of Health will be looking at every zloty spent. The coordination team for the treatment of atypical hemolytic uremic syndrome and the coordination team for the treatment of paroxysmal hemoglobinuria will control expenditure and patients will be tracked in registries.
According to the estimates of the Ministry of Health, several children who are currently waiting for treatment in CHD will benefit from the therapy in the first year.
As the minister explains, the budgetary consequences of this reimbursement will not be the same as in the case of highly prevalent diseases. – This decision is unique, it is absolutely unique when it comes to our logic of making reimbursement decisions. We must change the approach to the treatment of rare and ultra-rare diseases, announced Minister Marcin Czech.